Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-12-08

Study Completion Date

2013-09-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to provide subjects who participated in prior studies of EXC 001 the opportunity to have their hypertrophic scars surgically revised and treated with EXC 001.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety, Tolerability, Pharmacokinetics, Immunogenicity and Efficacy of STP705 in Adult Patients With Hypertrophic Scars

NCT05196373

Hypertrophic Scar

UNKNOWN PHASE1/PHASE2

A Phase 2 Extension Study To Enroll Subjects Who Were Enrolled In B5301001 Study

NCT02205476

Hypertrophic Scars Resulting From Prior Breast Scar Revision Surgery

TERMINATED PHASE2

Comparative Study Between CellFX and Electrodessication in Sebaceous Hyperplasia (SH) Lesions

NCT04539886

Skin Lesion Skin Abnormalities Sebaceous Hyperplasia

COMPLETED NA

A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar

NCT02956317

Hypertrophic Scar

COMPLETED PHASE1/PHASE2

Treatment of Epidermoid Cysts

NCT05597995

Epidermoid Cyst

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Reduction in Severity of Skin Scarring

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Open Label

Group Type EXPERIMENTAL

EXC 001 (currently called PF-06473871)

Intervention Type DRUG

Single dose administered by injection at four different times

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EXC 001 (currently called PF-06473871)

Single dose administered by injection at four different times

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy adults who have participated in previous studies of EXC 001.
* Healthy adults who have chosen to have their scars revised.

Exclusion Criteria

* Currently pregnant or pregnant during the 6 months prior to inclusion in the study, or breast feeding.
* Participation in another clinical trial within 30 days prior to the start of the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No